Vortioxetine Hydrobromide
Brand names: Trintellix
At a glance
- Medicare prescriptions, 2024
- 431,050
- Medicare drug cost
- $246.2M
- Average cost per prescription
- $571
- Clinicians who prescribed it
- 16,193
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults.
From the FDA-approved prescribing information (label dated March 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. TRINTELLIX is not approved for use in pediatric patients. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor for worsening and emergence of suicidal thoughts and behaviors. TRINTELLIX is not approved for use in pediatric patients.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 32.2%
- Psychiatric Nurse Practitioners 23.2%
- Family Medicine 12.8%
- Internal Medicine 10.3%
- Nurse Practitioners 10.1%
- Physician Assistants 5.2%
- Neurology 1.2%
- Child & Adolescent Psychiatry 1.2%
- Geriatric Medicine 0.8%
- General Practice 0.7%
- Hospitalist 0.2%
- Addiction Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 5% from 2019 to 2024.
Biggest change by state since 2019
- Oklahoma +76%
- Iowa +52%
- Minnesota +37%
- Wisconsin +30%
- Louisiana +29%
- Mississippi (smallest change) −13%
- Texas (smallest change) −9%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow tear tablet, 8 mm | 10 TL |
Takeda Pharmaceuticals America, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | pink tear tablet, 8 mm | 5 TL |
| 10 mg | yellow tear tablet, 8 mm | 10 TL |
| 20 mg | red tear tablet, 8 mm | 20 TL |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $688,564 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Takeda Pharmaceuticals U.S.A., Inc. $688,564
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.